Why does drug resistance readily evolve but vaccine resistance does not?

Proceedings of the Royal Society B: Biological Sciences

Volumn 284, Issue 1851, 2017, Pages

  Kennedy, David A ^a   Read, Andrew F ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Antimicrobial resistance; Evolutionary rescue; Pathogen evolution; Vaccine escape

Indexed keywords

ANTIMICROBIAL ACTIVITY; DRUG RESISTANCE; EVOLUTION; IMMUNE RESPONSE; POPULATION GENETICS; VACCINE;

VACCINE;

ANTIBIOTIC RESISTANCE; MOLECULAR EVOLUTION;

DRUG RESISTANCE, MICROBIAL; EVOLUTION, MOLECULAR; VACCINES;

EID: 85016458447     PISSN: 09628452     EISSN: 14712954     Source Type: Journal    
DOI: 10.1098/rspb.2016.2562     Document Type: Article

References (97)

1. Brueggemann AB, Pai R, Crook DW, Beall B. 2007 Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog. 3, e168. (doi:10.1371/journal.ppat.0030168)
2. Carman WF, Karayiannis P, Waters J, Thomas HC, Zanetti AR, Manzillo G, Zuckerman AJ. 1990 Vaccine-induced escape mutant of hepatitis B virus. Lancet 336, 325–329. (doi:10.1016/0140-6736(90)91874-A)
3. Hilleman MR. 1998 Six decades of vaccine development—a personal history. Nat. Med. 4, 507–514. (doi:10.1038/nm0598supp-507)
4. Plotkin SL, Plotkin SA. 2008 A short history of vaccination. In Vaccines: fifth edition (eds SA Plotkin, WA Orenstein, PA Offit), pp. 1–16. Philadelphia, PA: Elsevier Inc.
5. Hegerle N, Paris AS, Brun D, Dore G, Njamkepo E, Guillot S, Guiso N. 2012 Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin. Clin. Microbiol. Infect. 18, E340–E346. (doi:10.1111/j.1469-0691.2012.03925.x)
6. Centers for Disease Control and Prevention. 2015 Epidemiology and prevention of vaccine-preventable diseases, 13th edn (eds J Hambrosky, A Kroger, C Wolfe). Washington, DC: Public Health Foundation.
7. McClure NS, Day T. 2014 A theoretical examination of the relative importance of evolution management and drug development for managing resistance. Proc. R. Soc. B 281, 2014 1861. (doi:10.1098/rspb.2014.1861)
8. Larder BA, Darby G, Richman DD. 1989 HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243, 1731–1734. (doi:10.1126/science.2467383)
9. Ke R, Loverdo C, Qi H, Sun R, Lloyd-Smith JO. 2015 Rational design and adaptive management of combination therapies for hepatitis C virus infection. PLoS Comput. Biol. 11, e1004040. (doi:10.1371/journal.pcbi.1004040)
10. Mooi FR, van Oirschot H, Heuvelman K, van der Heide HGJ, Gaastra W, Willems RJL. 1998 Polymorphism in the Bordetella pertussis virulence factors p. 69/pertactin and pertussis toxin in the Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect. Immun. 66, 670–675.
11. Mishra RPN, Oviedo-Orta E, Prachi P, Rappuoli R, Bagnoli F. 2012 Vaccines and antibiotic resistance. Curr. Opin. Microbiol. 15, 596–602. (doi:10.1016/j.mib.2012.08.002)
12. zur Wiesch PA, Kouyos R, Engelstädter J, Regoes RR, Bonhoeffer S. 2011 Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect. Dis. 11, 236–247. (doi:10.1016/S1473-3099(10)70264-4)
13. Barber M, Whitehead JEM. 1949 Bacteriophage types in penicillin-resistant staphylococcal infection. Br. Med. J. 2, 565. (doi:10.1136/bmj.2.4627.565)
14. Davies J, Davies D. 2010 Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 74, 417–433. (doi:10.1128/MMBR.00016-10)
15. MacGowan A, Albur M. 2013 Frontline antibiotic therapy. Clin. Med. 13, 263–268. (doi:10.7861/clinmedicine.13-3-263)
16. Davies SC. 2013 Annual Report of the Chief Medical Officer, Volume Two, 2011. London, UK: Department of Health.
17. Fenner F. 1983 The Florey lecture, 1983: biological control, as exemplified by smallpox eradication and myxomatosis. Proc. R. Soc. Lond. B 218, 259–285. (doi:10.1098/rspb.1983.0039)
18. Lipsitch M, Siber GR. 2016 How can vaccines contribute to solving the antimicrobial resistance problem? mBio 7, e00428-16. (doi:10.1128/mBio. 00428-16)
19. Martcheva M, Bolker BM, Holt RD. 2008 Vaccine-induced pathogen strain replacement: what are the mechanisms? J. R. Soc. Interface 5, 3–13. (doi:10. 1098/rsif.2007.0236)
20. Harrison TJ, Hopes EA, Oon CJ, Zanetti AR, Zuckerman AJ. 1991 Independent emergence of a vaccine-induced escape mutant of hepatitis B virus. J. Hepatol. 13, S105–S107. (doi:10.1016/0168-8278(91)90037-C)
21. Schouls LM, van der Ende A, van de Pol I, Schot C, Spanjaard L, Vauterin P, Wilderbeek D, Witteveen S. 2005 Increase in genetic diversity of Haemophilus influenzae serotype b (Hib) strains after introduction of Hib vaccination in the Netherlands. J. Clin. Microbiol. 43, 2741–2749. (doi:10.1128/JCM.43.6. 2741-2749.2005)
22. Octavia S, Sintchenko V, Gilbert GL, Lawrence A, Keil AD, Hogg G, Lan R. 2012 Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008–2010. J. Infect. Dis. 205, 1220–1224. (doi:10.1093/infdis/jis178)
23. Drexler JF et al. 2014 Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010. Proc. Natl Acad. Sci. USA 111, 12 889–12 894. (doi:10.1073/pnas.1323502111)
24. Lam C et al. 2014 Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia. Emerg. Infect. Dis. 20, 626–633. (doi:10.3201/eid2004.131478)
25. Clark TA. 2014 Changing pertussis epidemiology: everything old is new again. J. Infect. Dis. 209, 978–981. (doi:10.1093/infdis/jiu001)
26. Romanò L, Paladini S, Galli C, Raimondo G, Pollicino T, Zanetti AR. 2015 Hepatitis B vaccination: are escape mutant viruses a matter of concern? Hum. Vaccin. Immunother. 11, 53–57. (doi:10. 4161/hv.34306)
27. Lu H, Tang Y, Dunn PA, Wallner-Pendleton EA, Lin L, Knoll EA. 2015 Isolation and molecular characterization of newly emerging avian reovirus variants and novel strains in Pennsylvania, USA, 2011–2014. Sci. Rep. 5, 14727. (doi:10.1038/srep14727)
28. Welch TJ, Verner-Jeffreys DW, Dalsgaard I, Wiklund T, Evenhuis JP, Cabrera JAG, Hinshaw JM, Drennan JD, LaPatra SE. 2011 Independent emergence of Yersinia ruckeri biotype 2 in the United States and Europe. App. Environ. Microb. 77, 3493–3499. (doi:10.1128/AEM.02997-10)
29. Lee CW, Senne DA, Suarez DL. 2004 Effect of vaccine use in the evolution of Mexican lineage H5N2 avian influenza virus. J. Virol. 78, 8372–8381. (doi:10.1128/JVI.78.15.8372-8381.2004)
30. Witter RL. 1997 Increased virulence of Marek’s disease virus field isolates. Avian Dis. 41, 149–163. (doi:10.2307/1592455)
31. Franzo G, Tucciarone CM, Cecchinato M, Drigo M. 2016 Porcine circovirus type 2 (PCV2) evolution before and after the vaccination introduction: a large scale epidemiological study. Sci. Rep. 6, 39458. (doi:10.1038/srep39458)
32. Read AF, Baigent SJ, Powers C, Kgosana LB, Blackwell L, Smith LP, Kennedy DA, Walkden-Brown SW, Nair VK. 2015 Imperfect vaccination can enhance the transmission of highly virulent pathogens. PLoS Biol. 13, e1002198. (doi:10.1371/journal.pbio.1002198)
33. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. 1998 Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178, 1257–1262. (doi:10.1086/314440)
34. de Jong MD et al. 2005 Oseltamivir resistance during treatment of influenza A (H5N1) infection. New Engl. J. Med. 353, 2667–2672. (doi:10.1056/NEJMoa054512)
35. Linnemann CC, Biron KK, Hoppenjans WG, Solinger AM. 1990 Emergence of acyclovir-resistant varicella zoster virus in an AIDS patient on prolonged acyclovir therapy. AIDS 4, 577–580. (doi:10.1097/00002030-199006000-00014)
36. Walling DM, Flaitz CM, Nichols CM. 2003 Epstein– Barr virus replication in oral hairy leukoplakia: response, persistence, and resistance to treatment with valacyclovir. J. Infect. Dis. 188, 883–890. (doi:10.1086/378072)
37. Frank SA, Bush RM. 2007 Barriers to antigenic escape by pathogens: trade-off between reproductive rate and antigenic mutability. BMC Evol. Biol. 7, 229. (doi:10.1186/1471-2148-7-229)
38. Kalland KH, Håvarstein L, Endresen C, Haukenes G. 1990 Stability of the nucleotide sequence of the phosphoprotein gene of measles virus during lytic infections. APMIS 98, 327–335. (doi:10.1111/j. 1699-0463.1990.tb01040.x)
39. Schrag SJ, Rota PA, Bellini WJ. 1999 Spontaneous mutation rate of measles virus: direct estimation based on mutations conferring monoclonal antibody resistance. J. Virol. 73, 51–54.
40. Fulton BO, Sachs D, Beaty SM, Won ST, Lee B, Palese P, Heaton NS. 2015 Mutational analysis of measles virus suggests constraints on antigenic variation of the glycoproteins. Cell Rep. 11, 1331– 1338. (doi:10.1016/j.celrep.2015.04.054)
41. McLean AR. 1995 Vaccination, evolution and changes in the efficacy of vaccines: a theoretical framework. Proc. R. Soc. Lond. B 261, 389–393. (doi:10.1098/rspb.1995.0164)
42. McLean AR. 1998 Vaccines and their impact on the control of disease. Br. Med. Bull. 54, 545–556. (doi:10.1093/oxfordjournals.bmb.a011709)
43. REX Consortium. 2013 Heterogeneity of selection and the evolution of resistance. Trends Ecol. Evol. 28, 110–118. (doi:10.1016/j.tree.2012.09.001)
44. Gandon S, Mackinnon MJ, Nee S, Read AF. 2001 Imperfect vaccines and the evolution of pathogen virulence. Nature 414, 751–756. (doi:10.1038/414751a)
45. Frank SA. 2002 Immunology and evolution of infectious disease. Princeton, NJ: Princeton University Press.
46. Mackinnon MJ, Gandon S, Read AF. 2008 Virulence evolution in response to vaccination: the case of malaria. Vaccine 26, C42–C52. (doi:10.1016/j.vaccine.2008.04.012)
47. Holmes EC. 2009 The evolutionary genetics of emerging viruses. Ann. Rev. Ecol. Evol. Syst. 40, 353–372. (doi:10.1146/annurev.ecolsys.110308.120248)
48. Gutiérrez S, Michalakis Y, Blanc S. 2012 Virus population bottlenecks during within-host progression and host-to-host transmission. Curr. Opin. Virol. 2, 546–555. (doi:10.1016/j.coviro.2012.08.001)
49. Smith RC, Vega-Rodríguez J, Jacobs-Lorena M. 2014 The Plasmodium bottleneck: malaria parasite losses in the mosquito vector. Mem. Inst. Oswaldo Cruz 109, 644–661. (doi:10.1590/0074-0276130597)
50. Ehrlich P. 1913 Chemotherapeutics: scientific principles, methods and results. Lancet 2, 353–359.
51. Ramsayer J, Kaltz O, Hochberg ME. 2013 Evolutionary rescue in populations of Pseudomonas fluorescens across an antibiotic gradient. Evol. Appl. 6, 608–616. (doi:10.1111/eva.12046)
52. Smith DW, Wiegeshaus E, Navalkar R, Grover AA. 1966 Host–parasite relationships in experimental airborne tuberculosis I. Preliminary studies in BCG-vaccinated and nonvaccinated animals. J. Bacteriol. 91, 718–724.
53. Zhu Y, Heath J, Collins J, Greene T, Antipa L, Rota P, Bellini W, McChesney M. 1997 Experimental measles. II. Infection and immunity in the rhesus macaque. Virology 233, 85–92. (doi:10.1006/viro.1997.8575)
54. Préziosi MP, Halloran ME. 2003 Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness. Vaccine 21, 1853–1861. (doi:10.1016/S0264-410X(03)00007-0)
55. Cardo DM et al. 1997 A case–control study of HIV seroconversion in health care workers after percutaneous exposure. New Engl. J. Med. 337, 1485–1490. (doi:10.1056/NEJM199711203372101)
56. Cabello FC. 2006 Heavy use of prophylactic antibiotics in aquaculture: a growing problem for human and animal health and for the environment. Environ. Microbiol. 8, 1137–1144. (doi:10.1111/j. 1462-2920.2006.01054.x)
57. Kunkel A, Colijn C, Lipsitch M, Cohen T. 2015 How could preventive therapy affect the prevalence of drug resistance? Causes and consequences. Phil. Trans. R. Soc. B 370, 20140306. (doi:10.1098/rstb.2014.0306)
58. Pena-Miller R, Laehnemann D, Jansen G, Fuentes-Hernandez A, Rosenstiel P, Schulenburg H, Beardmore R. 2013 When the most potent combination of antibiotics selects for the greatest bacterial load: the smile–frown transition. PLoS Biol. 11, e1001540. (doi:10.1371/journal.pbio.1001540)
59. Fish DN, Piscitelli SC, Danziger LH. 1995 Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 15, 279–291.
60. Bonhoeffer S, Lipsitch M, Levin BR. 1997 Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl Acad. Sci. USA 94, 12 106–12 111. (doi:10.1073/pnas.94.22.12106)
61. Bergstrom CT, Lo M, Lipsitch M. 2004 Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc. Natl Acad. Sci. USA 101, 13 285–13 290. (doi:10.1073/pnas.0402298101)
62. Boni MF, Smith DL, Laxminarayan R. 2008 Benefits of using multiple first-line therapies against malaria. Proc. Natl Acad. Sci. USA 105, 14 216– 14 221. (doi:10.1073/pnas.0804628105)
63. Nguyen TD, Olliaro P, Dondorp AM, Baird JK, Lam HM, Farrar J, Thwaites GE, White NJ, Boni MF. 2015 Optimum population-level use of artemisinin combination therapies: a modelling study. Lancet Glob. Health 3, e758–e766. (doi:10.1016/S2214-109X(15)00162-X)
64. Chesney MA, Morin M, Sherr L. 2000 Adherence to HIV combination therapy. Soc. Sci. Med. 50, 1599–1605. (doi:10.1016/S0277-9536(99)00468-2)
65. Gillespie SH. 2002 Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob. Agents Chemother. 46, 267–274. (doi:10.1128/AAC.46.2.267-274.2002)
66. Janeway CA, Travers P, Walport M, Capra JD. 2005 Immunobiology: the immune system in health and disease. New York, NY: Garland Science.
67. Davis MM, Bjorkman PJ. 1988 T-cell antigen receptor genes and T-cell recognition. Nature 334, 395–402. (doi:10.1038/334395a0)
68. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. 2002 Molecular biology of the cell. New York, NY: Garland Science.
69. Poulsen TR, Meijer PJ, Jensen A, Nielsen LS, Andersen PS. 2007 Kinetic, affinity, and diversity limits of human polyclonal antibody responses against tetanus toxoid. J. Immunol. 179, 3841–3850. (doi:10.4049/jimmunol.179.6.3841)
70. Li H, Ye C, Ji G, Han J. 2012 Determinants of public T cell responses. Cell Res. 22, 33–42. (doi:10.1038/cr.2012.1)
71. Yewdell JW, Webster RG, Gerhard WU. 1979 Antigenic variation in three distinct determinants of an influenza type A haemagglutinin molecule. Nature 279, 246–248. (doi:10.1038/279246a0)
72. Price DA et al. 2004 T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity 21, 793–803. (doi:10.1016/j. immuni.2004.10.010)
73. Schotte L, Thys B, Strauss M, Filman DJ, Rombaut B, Hogle JM. 2015 Characterization of poliovirus neutralization escape mutants of single-domain antibody fragments (VHHs). Antimicrob. Agents Chemother. 59, 4695–4706. (doi:10.1128/AAC. 00878-15)
74. Radford AD, Dawson S, Coyne KP, Porter CJ, Gaskell RM. 2006 The challenge for the next generation of feline calicivirus vaccines. Vet. Microbiol. 117, 14–18. (doi:10.1016/j.vetmic.2006.04.004)
75. Barclay VC, Sim D, Chan BHK, Nell LA, Rabaa MA, Bell AS, Anders RF, Read AF. 2012 The evolutionary consequences of blood-stage vaccination on the rodent malaria Plasmodium chabaudi. PLoS Biol. 10, e1001368. (doi:10.1371/journal.pbio.1001368)
76. Austin DA, Robertson PAW, Austin B. 2003 Recovery of a new biogroup of Yersinia ruckeri from diseased rainbow trout (Oncorhynchus mykiss, Walbaum). Syst. Appl. Microbiol. 26, 127–131. (doi:10.1078/072320203322337416)
77. O’Brien KL et al. 2007 Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J. Infect. Dis. 196, 1211–1220. (doi:10.1086/521833)
78. Lipsitch M. 1997 Vaccination against colonizing bacteria with multiple serotypes. Proc. Natl Acad. Sci. USA 94, 6571–6576. (doi:10.1073/pnas.94.12.6571)
79. Weinberger DM, Malley R, Lipsitch M. 2011 Serotype replacement in disease after pneumococcal vaccination. Lancet 378, 1962–1973. (doi:10.1016/S0140-6736(10)62225-8)
80. Zanetti AR, Tanzi E, Manzillo G, Maio G, Sbreglia C, Caporaso N, Thomas H, Zuckerman AJ. 1988 Hepatitis B variant in Europe. Lancet 2, 1132–1133. (doi:10.1016/S0140-6736(88)90541-7)
81. Sheldon J, Soriano V. 2008 Hepatitis B virus escape mutants induced by antiviral therapy. J. Antimicrob. Chemother. 61, 766–768. (doi:10.1093/jac/dkn014)
82. Kallonen T, He Q. 2009 Bordetella pertussis strain variation and evolution postvaccination. Expert Rev. Vaccines 8, 863–875. (doi:10.1586/erv.09.46)
83. Warfel JM, Zimmerman LI, Merkel TJ. 2014 Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc. Natl Acad. Sci. USA 111, 787–792. (doi:10.1073/pnas.1314688110)
84. Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, Guiso N. 2009 First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. Vaccine 27, 6034–6041. (doi:10.1016/j.vaccine.2009.07.074)
85. Hegerle N, Guiso N. 2014 Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines. Expert Rev. Vaccines 13, 1135–1146. (doi:10.1586/14760584.2014.932254)
86. Martin SW et al. 2015 Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage. Clin. Infect. Dis. 60, 223–227. (doi:10.1093/cid/ciu788)
87. Safarchi A, Octavia S, Luu LDW, Tay CY, Sintchenko V, Wood N, Marshall H, McIntyre P, Lan R. 2015 Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model. Vaccine 33, 6277–6281. (doi:10.1016/j.vaccine.2015.09.064)
88. Woods RJ, Read AF. 2015 Clinical management of resistance evolution in a bacterial infection: a case study. Evol. Med. Public Health 2015, 281–288. (doi:10.1093/emph/eov025)
89. Andersson DI, Hughes D. 2014 Microbiological effects of sublethal levels of antibiotics. Nat. Rev. Microbiol. 12, 465–478. (doi:10.1038/nrmicro3270)
90. D’Costa VM et al. 2011 Antibiotic resistance is ancient. Nature 477, 457–461. (doi:10.1038/nature10388)
91. Lavine JS, King AA, Bjørnstad ON. 2011 Natural immune boosting in pertussis dynamics and the potential for long-term vaccine failure. Proc. Natl Acad. Sci. USA 108, 7259–7264. (doi:10.1073/pnas.1014394108)
92. Gupta S, Ferguson N, Anderson R. 1998 Chaos, persistence, and evolution of strain structure in antigenically diverse infectious agents. Science 280, 912–915. (doi:10.1126/science.280.5365.912)
93. Cobey S, Lipsitch M. 2012 Niche and neutral effects of acquired immunity permit coexistence of pneumococcal serotypes. Science 335, 1376–1380. (doi:10.1126/science.1215947)
94. Koff WC, Burton DR, Johnson PR, Walker BD, King CR, Nabel GJ, Ahmed R, Bhan MK, Plotkin SA. 2013 Accelerating next-generation vaccine development for global disease prevention. Science 340, 1232910. (doi:10.1126/science.1232910)
95. Carrat F, Flahault A. 2007 Influenza vaccine: the challenge of antigenic drift. Vaccine 25, 6852– 6862. (doi:10.1016/j.vaccine.2007.07.027)
96. Corti D, Lanzavecchia A. 2013 Broadly neutralizing antiviral antibodies. Ann. Rev. Immunol. 31, 705– 742. (doi:10.1146/annurev-immunol-032712-095916)
97. Euler Z, Bunnik EM, Burger JA, Boeser-Nunnink BD, Grijsen ML, Prins JM, Schuitemaker H. 2011 Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic. J. Virol. 85, 7236–7245. (doi:10.1128/JVI.00196-11)